Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose:
Anti-prothrombin antibodies (aPT) either alone or in association with other anti-phospholipid antibodies have been associated with an increased risk of thrombosis as well as of adverse obstetric outcomes particularly, recurrent early miscarriages.To assess whether anti-prothrombin antibodies have a predictive significance for the occurrence of late obstetric complications and maternal events in patients with SLE and APS
Methods:
Sera from pregnant patients with SLE and APS collected during the first trimester of pregnancy were examined for the presence of anti-prothrombin antibodies (aPT), anticardiolipin antibodies (aCL), anti-B2GPI antibodies, Lupus anticoagulant (LA). Pregnancies were prospectively followed. The following obstetric complications were considered: preterm delivery, pre-eclampsia, eclampsia, intrauterine growth retardation, intrauterine fetal death. In addition the occurrence of maternal thrombotic complications was recorded.
Results:
Seventy six pregnancies in 60 patients (18 APS and 52 SLE) with a duration >10 weeks were included in the analysis. Anti-phospholipid antibodies were positive in 26 patients (aCL 25, LA 17, aPT 16 , anti- B2GPI 6). Pregnancy outcomes are reported in the table 1.
A significant correlation was observed between the presence of anti-prothrombin antibodies and the occurrence of obstetric complications (p<0.05). The positivity of anti-prothrombin antibodies in addition to either positive aCL, anti-B2GPI and/or LA increased the risk of developing late obstetric complications (p< 0.001). No correlations were observed between the presence of anti-prothrombin antibodies alone or multiple anti-phospholipid antibodies and the occurrence of maternal thrombotic events.
Conclusion:
The presence of aPT antibodies appears associated with an increased risk for late obstetric complications in SLE and APS and therefore their assessment is suggested in these patients at the beginning of pregnancy.
|
|
SLE |
APS |
Whole group |
|
IUFD |
2 |
3 |
5 |
|
Perinatal death |
0 |
1 |
1 |
|
Preterm delivery |
17 |
12 |
29 |
|
IUGR |
7 |
1 |
8 |
|
Pre-eclampsia |
7 |
4 |
11 |
|
HELLP |
0 |
2 |
2 |
|
Maternal thrombotic manifestations |
2 |
3 |
5 |
Disclosure:
M. Mosca,
None;
C. Tani,
None;
M. Fabris,
None;
F. Strigini,
None;
L. Carli,
None;
S. Vagnani,
None;
R. Talarico,
None;
C. Baldini,
None;
A. Della Rossa,
None;
E. Tonutti,
None;
S. Bombardieri,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-significance-of-anti-prothrombin-antibodies-for-second-and-third-trimester-obstetric-complications-in-patients-with-systemic-lupus-erythematosus-and-anti-phospholipid-syndrome/